Speaker Profile

M.D., CEO, Poseida Therapeutics

Biography
Dr. Ostertag directed Poseida’s spin out from Transposagen in February 2015 and has served as our chief executive officer and as a member of our board of directors since May 2015. From October 2003 to July 2015, Dr. Ostertag founded and served as the chief executive officer and president of Transposagen Biopharmaceuticals, Inc., a biotechnology company that commercializes early gene editing technology in the research reagent space. Dr. Ostertag previously co-founded and served as chief executive officer and president of Vindico NanoBioTechnology, Inc., a biotechnology company engaged in the discovery, development, and commercialization of human therapeutics that are based on a nanometer-scale particulate technology. Dr. Ostertag also co-founded and served as executive vice president of PhenoTech, Inc., a biotechnology company engaged in the discovery, development, and commercialization of reagents for diagnostic use in blood banks.

Talk
​A Novel Approach To CAR-T Therapy​
CART Therapeutics comprised of a high percentage of stem cell memory T cells exhibit unique properties that could potentially solve most of the limitations of early-generation CART products, including significant toxicities, historically poor efficacy against solid tumors, and high costs.


 Session Abstract – PMWC 2020 Silicon Valley


CAR-T cell therapy has evolved from an arcane approach under study in a handful of academic centers to a commercialized immunotherapy that is now being integrated into standard cancer care. The session will highlight some of the recent scientific advances that have begun to define major mechanisms of resistance to CAR-T cell therapy in B cell malignancies and identify the challenges that need to be addressed if these agents are to find broader applications in other hematological cancers and solid tumors.